Thrivent Financial for Lutherans Has $4.05 Million Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Thrivent Financial for Lutherans increased its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 6.4% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 138,862 shares of the company’s stock after acquiring an additional 8,358 shares during the period. Thrivent Financial for Lutherans owned about 0.10% of Denali Therapeutics worth $4,045,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DNLI. Point72 Asset Management L.P. acquired a new position in shares of Denali Therapeutics during the second quarter worth about $24,454,000. Integral Health Asset Management LLC bought a new position in shares of Denali Therapeutics during the 2nd quarter worth approximately $7,546,000. Candriam S.C.A. grew its stake in shares of Denali Therapeutics by 62.2% during the 2nd quarter. Candriam S.C.A. now owns 726,499 shares of the company’s stock worth $16,869,000 after acquiring an additional 278,621 shares in the last quarter. Marshall Wace LLP raised its holdings in shares of Denali Therapeutics by 12.7% in the second quarter. Marshall Wace LLP now owns 2,418,833 shares of the company’s stock valued at $56,165,000 after purchasing an additional 272,454 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Denali Therapeutics by 58.7% in the second quarter. Millennium Management LLC now owns 619,929 shares of the company’s stock worth $14,395,000 after purchasing an additional 229,313 shares in the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have commented on DNLI shares. Raymond James reissued a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th. Wedbush lowered their price target on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. HC Wainwright reissued a “buy” rating and issued a $90.00 price objective on shares of Denali Therapeutics in a report on Thursday, November 7th. Bank of America upped their price target on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Finally, Citigroup lifted their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $38.90.

Denali Therapeutics Trading Up 1.9 %

NASDAQ:DNLI opened at $24.69 on Monday. The stock has a market cap of $3.55 billion, a P/E ratio of -8.95 and a beta of 1.40. The stock has a 50 day simple moving average of $27.88 and a 200 day simple moving average of $24.33. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same quarter in the prior year, the business posted ($0.72) EPS. As a group, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.69 EPS for the current year.

Insiders Place Their Bets

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, September 30th. The shares were sold at an average price of $29.03, for a total transaction of $870,900.00. Following the transaction, the director now owns 29,096 shares in the company, valued at $844,656.88. The trade was a 50.76 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the completion of the sale, the chief executive officer now owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This represents a 14.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 86,578 shares of company stock valued at $2,474,440. 7.90% of the stock is currently owned by corporate insiders.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.